What Cumulus Neuroscience does

Cumulus Neuroscience Limited is a Belfast-headquartered (UK) private digital-health company that develops the NeuLogiq Platform, an integrated multi-modal biomarker system combining a tablet-based cognitive assessment battery, a wireless dry-sensor EEG headset (FDA 510(k) cleared and UKCA marked in 2023), and proprietary machine-learning analytics for CNS clinical trials. The company deploys the platform exclusively for use in biopharma-sponsored clinical studies — Phase 0 through Phase 3 — and does not sell it for individual or standalone in-clinic use; revenue is generated through enterprise clinical-trial contracts supported by an in-house Clinical Operations and Scientific team. Its core customers are global pharmaceutical companies developing CNS therapeutics in Alzheimer's disease, neuropsychiatry, and other neurodegenerative indications, and the platform was co-designed with ten top pharma companies (J&J, Lilly, MSD, Pfizer, Roche, Takeda, Biogen, Boehringer Ingelheim, BMS, GSK) through the Cumulus Pharma Advisory Group (CPAG).

The business operates with offices in Belfast, Dublin, and a Japan clinical operations presence, deploying studies across the UK, US, Europe, Canada, Australia, and Japan. Revenue mechanics are enterprise-direct (multi-year, quote-based trial contracts) with the platform functioning as both a clinical-trial endpoint instrument and a longitudinal real-world data collection system. Beyond the core trial-deployment business, Cumulus is developing AccelADx, an AI-enabled Alzheimer's screening test being validated in the 1,000+ participant Bio-Hermes 2 study, supported by ~£2.2M of Innovate UK grant funding in 2024. The company has raised approximately £9.25M in disclosed equity (2020 seed, £6M in May 2021 led by DDF/LifeArc/UK Future Fund, £3.25M in July 2025 led by Whiterock Finance) and is led by CEO Tina Sampath (ex-Gilead, Pfizer, Blue Earth Diagnostics) with co-founder Brian Murphy, PhD as CSO; the Board is chaired by Ricardo Sáinz Fuertes, MD (Eisai) since January 2026.

Name

Cumulus Neuroscience

Legal name

Cumulus Neuroscience Limited

Website

https://cumulusneuro.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Cumulus Neuroscience builds the NeuLogiq Platform — an FDA 510(k)-cleared multi-modal digital biomarker system combining tablet-based cognitive assessments, dry-sensor EEG, and proprietary ML analytics — deployed exclusively into CNS clinical trials for global biopharma sponsors including J&J, Lilly, Pfizer, Roche, Takeda, Biogen, and others.

Ownership category

akta.pro rank

Product category

CNS Clinical Trial Technology / Digital Biomarker Platform

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Scientific and Technical Consulting Services (54169)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Medical Laboratories (8071)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industry

Decentralized/Hybrid Trial Enablement (DCT) Platforms (HLACAOAL)

Keywords

• CNS clinical trials
• Digital biomarker platform
• EEG brain monitoring
• Alzheimer's disease research
• Neurodegenerative drug development

Headquarters

HQ city

Belfast

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. CNS Clinical Trial Platform Deployment: Cumulus Neuroscience deploys the NeuLogiq Platform solely for use in clinical studies — the company does not sell the platform for individual or in-clinic standalone use. Revenue is generated via clinical trial deployments with biopharma sponsors, supported by Clinical Operations and Scientific teams through trial design, deployment, and analysis. Likely structured as project- or study-based fees or multi-study licensing contracts.
2. Recurring / Repeat Study Engagements: The NeuLogiq Platform supports the full clinical development lifecycle from small Phase 0 to large global Phase 3 studies, enabling land-and-expand across multiple studies with the same biopharma sponsor. End-to-end operational, technical, and scientific support drives recurring revenue across trial phases.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Cumulus Neuroscience operates the NeuLogiq Platform, an integrated physiological and digital biomarker platform that combines an FDA 510(k)-cleared and UKCA-marked dry-sensor EEG headset, tablet-based cognitive assessments, and AI-powered analytics to deliver frequent, reliable in-clinic and at-home longitudinal monitoring of brain function for CNS clinical trials. The platform is deployed solely for use in clinical studies with biopharma sponsors, supported by in-house Clinical Operations and Scientific teams, and is not sold for individual or standalone in-clinic use. Alongside the platform, Cumulus offers AccelADx, an AI-enabled Alzheimer's screening test being validated in the Bio-Hermes 2 study.

Product overview

Cumulus Neuroscience offers a single unified platform — the NeuLogiq Platform — composed of four tightly integrated modules: the FDA 510(k)-cleared and UKCA-marked NeuLogiq EEG Headset (hardware), the multi-modal NeuLogiq Assessment Suite (cognition, EEG, mood, speech, sleep), NeuLogiq AI Powered Analytics (proprietary ML/signal processing), and the NeuLogiq Study Management Hub (automated AI-powered dashboards). Together these deliver frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions for CNS clinical trials. Alongside the platform, Cumulus also offers AccelADx, an AI-enabled screening test for early detection of Alzheimer's disease being validated in the Bio-Hermes 2 study. The company deploys the NeuLogiq Platform solely for use in clinical studies with biopharma sponsors; it does not sell the platform for individual or in-clinic use.

Differentiator

Problem solved

Functional benefit

Brands

• NeuLogiq Platform: Cumulus Neuroscience's flagship unified platform integrating tablet-based cognitive assessments, longitudinal EEG, and AI-powered analytics for frequent, reliable in-clinic and at-home monitoring of brain function in CNS clinical trials.
• AccelADx

Products and services

• NeuLogiq Platform Unified clinical trial platform combining an FDA 510(k)-cleared and UKCA-marked dry-sensor EEG headset, tablet-based multi-modal cognitive and behavioural assessments, proprietary AI-powered analytics, and an automated Study Management Hub. Deployed by Cumulus solely for use in CNS clinical trials with biopharma sponsors from Phase 0 through Phase 3, in-clinic or at home, across the UK, US, Europe, Australia, Canada, and Japan.
• AccelADx

Quantifiable outcome

• At-home digital endpoints more sensitive to Alzheimer's disease progression than traditional clinical scales; can reduce trial costs and patient burden while providing earlier efficacy signals
• +2 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature7 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• Cumulus Pharma Advisory Group (CPAG)flagshipStrategic or Co-development PartnerA working group of 10 top pharma companies (J&J, Lilly, MSD, Pfizer, Roche, Takeda, Biogen, Boehringer Ingelheim, BMS, GSK) that co-designed the NeuLogiq Platform. Formed in 2020, CPAG continues to provide scientific guidance and feasibility-study collaboration.
• Global Alzheimer's Platform Foundation (GAP)coreStrategic or Co-development PartnerCumulus is deploying its AccelADx AI-enabled screening test in the Bio-Hermes 2 study, a 1,000+ participant observational study across the US, Canada, and Europe. The Bio-Hermes study is run by GAP and evaluates digital biomarkers against current Alzheimer's diagnostic standards.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cambridge Cognition: UK-based digital neuroscience company offering computerized cognitive assessments (CANTAB) and speech-based biomarkers (via Winterlight Labs acquisition) for CNS clinical trials. Directly comparable to Cumulus as a CNS clinical-trial endpoint vendor with biopharma sponsors, though more focused on cognitive testing than EEG hardware.
• Cogstate: Australia/US-listed cognitive assessment vendor whose computerized tests are widely used as endpoints in Alzheimer's, depression and other CNS clinical trials. Directly comparable business model of selling validated digital cognitive endpoints into biopharma-sponsored CNS studies.
• VivoSense: Digital biomarker company developing wearable sensor-derived endpoints (including some CNS-adjacent measures) for use as clinical trial outcomes. Comparable in providing regulatory-grade digital biomarker endpoints to biopharma sponsors for clinical studies, particularly in CNS and rare disease.
• ActiGraph: Provider of wearable actigraphy and digital health technology used to capture digital endpoints in clinical research, including CNS studies. Comparable in deploying regulated hardware (FDA-cleared) and analytics software to biopharma sponsors for clinical trial endpoint generation.

Broad incumbents

• Clario: Large clinical-trial technology vendor formed from the merger of Bioclinica, CRF Health and ERT, offering eCOA, imaging, cardiac safety and digital biomarker solutions across therapeutic areas. Comparable to Cumulus in CNS digital endpoints but with substantially broader portfolio, deeper enterprise relationships and larger scale.
• IQVIA: World's largest CRO with a digital health center of excellence (led by Cumulus board director Robert Ballantine) and growing capabilities in decentralized trials and digital biomarkers. Adjacent incumbent whose eCOA and decentralized trial offerings overlap with NeuLogiq's value proposition at much greater scale.
• Medidata (Dassault Systèmes): Major clinical-trial technology platform (Rave EDC, eCOA, decentralized trials, sensor cloud) widely used by biopharma sponsors globally. Comparable as a clinical-trial endpoint and data capture platform, though broader in scope than Cumulus's CNS-focused NeuLogiq offering.

Emerging players

• Linus Health: Digital health company focused on AI-enabled cognitive assessment and early detection of Alzheimer's and other dementias, with both clinical-trial and consumer-facing products. Comparable to Cumulus in CNS digital biomarker development but with a more consumer/clinic focus rather than pharma trial deployment.
• Empatica: Developer of FDA-cleared wearable biosensors (EpiMonitor, Embrace) and digital biomarkers used in neurology clinical trials and patient monitoring. Comparable in deploying regulated wearable hardware + AI analytics into CNS clinical research, though more focused on seizure/movement disorders.
• Winterlight Labs: Speech biomarker company (now part of Cambridge Cognition) developing voice-based digital endpoints for CNS trials in Alzheimer's, Parkinson's and depression. Comparable to Cumulus's language/speech assessment component of NeuLogiq and as a digital endpoint vendor to biopharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cumulusneuroscience
• Xx.com/CumulusNeuro
• Facebookfacebook.com/CumulusNeuroscience

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cumulus Neuroscience